iRhythm Technologies

pharma

San Francisco, CA · IRTC · Public

iRhythm Technologies is experiencing strong momentum with 25.7% revenue growth, improved profitability, and a favorable Medicare coverage update driving business expansion. The company is advancing AI-driven margin initiatives and maintaining strategic partnerships with Verily Life Sciences while managing a recent cybersecurity incident with no impact on device systems.

iRhythm Technologies, Inc. is a digital healthcare enterprise dedicated to offering portable electrocardiogram (ECG) monitoring solutions to individuals in the United States who face the risk of cardiac arrhythmias. Its primary offering, the Zio service, provides a comprehensive ambulatory cardiac monitoring system. This system ingeniously combines a wireless, patch-based, and wearable biosensor—specifically embodied in products like the Zio XT and AT monitors—with a sophisticated cloud-based data analysis platform. These single-use biosensors precisely record a patient's heartbeats and ECG data, thereby enabling medical professionals to effectively oversee patient heart health and accurately diagnose arrhythmias. Furthermore, iRhythm maintains a strategic development partnership with Verily Life Sciences LLC, focused on pioneering future atrial fibrillation screening, detection, and monitoring innovations. Founded in 2006, the company maintains its corporate headquarters in San Francisco, California.

Employees

2,000

Mfg Plants

All Facilities

Activity

7/10

Type

Public